Back to Search
Start Over
RNA Silencing in the Management of Dyslipidemias.
- Source :
- Current Atherosclerosis Reports; Nov2021, Vol. 23 Issue 11, p1-9, 9p
- Publication Year :
- 2021
-
Abstract
- Purpose of Review: Remarkable reductions in cardiovascular morbidity and mortality have been achieved in recent decades through the widespread use of 'small-molecule' hypolipidaemic drugs such as statins and ezetimibe. An alternative approach is to perturb the production of proteins through ribonucleic acid (RNA) silencing, leading to long-lasting knock-down of specific biological molecules. This review describes the scientific basis of RNA silencing, and critically evaluates the evidence relating to inclisiran, a small interfering RNA against proprotein convertase subtilisin kexin 9 (PCSK9). Recent Findings: Pooled analysis of three recent ORION trials has demonstrated that twice-yearly administration of inclisiran reduces LDL-C by 50% in a range of patient groups, with only mild adverse effects. Summary: Inclisiran provides safe, effective and long-lasting reductions in PCSK9 and LDL-C. The results of the phase-3 ORION-4 outcomes study are eagerly awaited. Further promising RNA silencing technologies have the potential to improve the management of dyslipidaemia. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 15233804
- Volume :
- 23
- Issue :
- 11
- Database :
- Complementary Index
- Journal :
- Current Atherosclerosis Reports
- Publication Type :
- Academic Journal
- Accession number :
- 152211306
- Full Text :
- https://doi.org/10.1007/s11883-021-00968-7